Shares of SCYNEXIS Inc (NASDAQ:SCYX) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $5.29.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered SCYNEXIS from a “buy” rating to a “hold” rating in a research report on Tuesday, March 12th. Maxim Group reissued a “buy” rating and set a $4.00 target price on shares of SCYNEXIS in a research report on Monday, March 18th. Finally, Brookline Capital Management reissued a “buy” rating on shares of SCYNEXIS in a research report on Friday, January 4th.
Shares of NASDAQ SCYX opened at $1.51 on Tuesday. The company has a current ratio of 8.76, a quick ratio of 8.76 and a debt-to-equity ratio of 0.48. SCYNEXIS has a fifty-two week low of $0.35 and a fifty-two week high of $2.15. The stock has a market cap of $78.23 million, a PE ratio of -3.08 and a beta of 2.34.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.